A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Researchers from across the country believe they have developed a breakthrough weight loss drug treatment: two new peptide compounds that could rival popular drugs like Ozempic and Wegovy ...

The company offers a wide range of drugs that can help you lose weight, including ones that contain Semaglutide, the active ingredient in popular medications like Ozempic and Wegovy. The one ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days in the fridge. Compounded semaglutide, which contains the same active ...

What's more, the FDA lists semaglutide, the compound in Ozempic and the weight loss drug Wegovy, as currently in shortage. "Many people, unfortunately, cannot get it," Hoenig told The Times.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient ... represent the views of Lee Enterprises. The publisher does not endorse or evaluate the advertised products ...

There was a robust positive correlation between public online search activity for semaglutide and tirzepatide and their prescription trends. The joint surge in prescriptions and online searches ...